EuroBiotech: More Articles of Note

TiGenix priced its Nasdaq IPO, both the U.K.'s ABPI and Europe's EFPIA gained new leaders, while Ipsen lost its CSO.

> Ipsen has said that Claude Bertrand will step down as EVP, R&D and CSO with Alexandre Lebeaut to lead its research and development division in the interim. Capital story

> AstraZeneca’s U.K. head Lisa Anson has been elected as the next president of the Association of the British Pharmaceutical Industry (ABPI), the main pharma R&D trade group in Britain, starting in April. Release

> The European trade group for pharma R&D is also going through changes at the top, as EFPIA announces its long-term director-general Richard Bergström is to leave. EFPIA said it has appointed Eric Cornut as its interim director general. Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Belgium biotech TiGenix has raised $35.65 million gross under its Nasdaq IPO, representing 46 million ordinary shares, at a price to the public of $15.50—a 14% discount on its shares. The company, which works on injectable stem cell therapies for perianal fistulas, plans to list on the Nasdaq under the symbol $TIG. Release

Suggested Articles

Bio-Rad Laboratories received FDA clearance for two digital PCR products designed to monitor CML patients’ molecular responses to treatment.

Neuspera Medical raised a total of $26 million through the second tranche of a series B round, to fund clinical testing programs for its implants.

Voyager stands to receive up to $728 million in milestones for each compound AbbVie chooses to advance beyond phase 1.